PPMD is thrilled to award two exploratory grants as part of our ongoing grant program. Peter Arthur of the University of Western Australia was awarded $50,000 to finish testing a molecule called procysteine in animal models in preparation for a human clinical trial. Procysteine is an antioxidant that has been tested in other disorders and has been shown to correct some of the defects caused by the lack of dystrophin in mice.
PPMD has also awarded ReveraGen BioPharma an Exploratory Award of $50,000 to determine if small snippets of RNA called "microRNAs" can affect the efficiency of exon-skipping. The investigators will inhibit the microRNAs that seem to be problematic while introducing antisense oligos to stimulate exon skipping.